- Home
- MGRX vs ENLV Comparison
MGRX vs ENLV Comparison
Compare MGRX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | ENLV |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.0M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MGRX | ENLV |
|---|---|---|
| Price | $0.20 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 378.6K | 263.0K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $456,021.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.16 |
| 52 Week High | $2.28 | $7.64 |
Technical Indicators
Market Signals| Indicator | MGRX | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 52.95 |
| Support Level | N/A | $0.55 |
| Resistance Level | $0.48 | $2.89 |
| Average True Range (ATR) | 0.03 | 0.23 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 22.50 | 39.56 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.